PORTHOS - PORTuguese Heart Failure Observational Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6189 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-30

Study Completion Date

2023-09-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to determine the prevalence of heart failure in the resident population in mainland Portugal aged 50 years or above, using a contemporary, guideline-based diagnostic approach, to optimize patient management and improve strategic healthcare decision-making

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Screening Of Adult urBan pOpulation To diAgnose Heart Failure

NCT03526601

Heart Failure

UNKNOWN

Heart Failure Evaluation Study

NCT05583513

Heart Failure

COMPLETED

NT-proBNP in the Optimization of Treatment After Recent Acute Heart Failure Trial

NCT00498472

Acute Heart Failure

COMPLETED PHASE4

Efficacy of a Streamlined Heart Failure Optimization Protocol

NCT05021419

Heart Failure with Reduced Ejection Fraction Chronic Heart Failure

COMPLETED NA

PROMs From GEstIC Heart Failure Patients

NCT06938698

Heart Failure

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The contemporary prevalence of heart failure in Portugal is largely unknown and may differ from that reported in early studies, which were conducted in the late 1990s-early 2000s with the diagnostic techniques available at the time and did not include neither advanced echocardiographic parameters nor natriuretic peptides measurements. Thus, a large and representative study is needed to address knowledge gaps on the epidemiology, characteristics and burden of heart failure in Portugal. The study aims to determine the prevalence of global heart failure, as well as heart failure subtypes. It also aims to assess the distribution of comorbidities among patients with heart failure, as well as patients' health-related quality of life. The Investigators will conduct a population-based study with a three-stage design approach, enrolling 5616 subjects aged 50 years or above, randomly selected through multi-stage sampling, using the National Health Service as reference: PHASE 0 - Participant selection/enrollment through phone call; PHASE 1 - Screening (NT-proBNP levels determination), health-related quality of life evaluation and sociodemographic characterization; PHASE 2 - Confirmatory assessment with a 12-lead electrocardiography, comprehensive transthoracic echocardiography, extended symptoms assessment and biomarkers assessment; PHASE 3 - Heart failure with preserved ejection fraction exertion testing through a non-invasive echocardiographic diastolic stress test.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Community-dwelling citizens living in Mainland Portugal;
* Registration in a primary care centre;
* Age ≥50 years at recruitment;
* Voluntary signed informed consent.

Exclusion Criteria

* Living in institutions (e.g., nursing homes, prisons, military facilities, hospitals);
* Non-Portuguese speakers;
* Reduced physical and/or cognitive ability hampering participation (e.g., blindness, deafness, or cognitive impairment).

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No